New York, New York - March 25, 2026 - PRESSADVANTAGE - Silverback AI Chatbot has released an announcement detailing its ...
New York, New York - March 17, 2026 - PRESSADVANTAGE - Silverback AI Chatbot has released an announcement outlining the ...
March 06, 2026 - PRESSADVANTAGE - Silverback Webinar has announced updates to its webinar software platform, expanding ...
March 12, 2026 - PRESSADVANTAGE - Silverback Webinar has issued an announcement outlining the functionality and ...
New York, New York - March 10, 2026 - PRESSADVANTAGE - Silverback AI Chatbot has announced the continued development ...
The case alleges that the Offering Documents and Silverback and its senior executives made misleading statements to investors and failed to disclose that: (i) Silverback's lead product candidate ...
As Silverback admits defeat, ARS troops forward to fund commercialization of epinephrine nasal spray
ARS Pharmaceuticals is backing onto Nasdaq through a reverse merger with Silverback Therapeutics to bag cash to commercialize an epinephrine nasal spray and win market share from the incumbent EpiPen.
Silverback Therapeutics will lay off 27% of its workforce and close its oncology program, the Seattle company announced Thursday in its fourth quarter earnings report. The company reported ...
SBT6290 Shown to Activate Myeloid Cells and Drive Anti-tumor Effects in Nectin4-expressing Solid Tumors “SBT6290 showcases the versatility of our ImmunoTAC platform and along with our lead program ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results